Association of clinic and ambulatory blood pressure with new-onset atrial fibrillation: A meta-analysis of observational studies.
Francesca CoccinaAnna M PierdomenicoMatteo De RosaChiara CuccurulloSante Donato PierdomenicoPublished in: Journal of clinical hypertension (Greenwich, Conn.) (2021)
The aim of this study was to perform a meta-analysis of studies evaluating the association of clinic and daytime, nighttime, and 24-h blood pressure with the occurrence of new-onset atrial fibrillation. We conducted a literature search through PubMed, Web of science, and Cochrane Library for articles evaluating the occurrence of new-onset atrial fibrillation in relation to the above-mentioned blood pressure parameters and reporting adjusted hazard ratio and 95% confidence interval. We identified five studies. The pooled population consisted of 7224 patients who experienced 444 cases of atrial fibrillation. The overall adjusted hazard ratio (95% confidence interval) was 1.05 (0.98-1.13), 1.19 (1.11-1.27), 1.18 (1.11-1.26), and 1.23 (1.14-1.32), per 10-mmHg increment in clinic, daytime, nighttime, and 24-h systolic blood pressure, respectively. The degree of heterogeneity of the hazard ratio estimates across the studies (Q and I-squared statistics) were minimal. The results of this meta-analysis strongly suggest that ambulatory systolic blood pressure prospectively predicts incident atrial fibrillation better than does clinic systolic blood pressure and that daytime, nighttime, and 24-h systolic blood pressure are similarly associated with future atrial fibrillation.
Keyphrases
- blood pressure
- atrial fibrillation
- hypertensive patients
- catheter ablation
- heart rate
- oral anticoagulants
- left atrial
- left atrial appendage
- heart failure
- systematic review
- direct oral anticoagulants
- primary care
- obstructive sleep apnea
- risk assessment
- percutaneous coronary intervention
- case control
- blood glucose
- cardiovascular disease
- metabolic syndrome
- sleep quality
- emergency department
- depressive symptoms
- single cell
- randomized controlled trial
- coronary artery disease